Abstract
Objective:
To evaluate whether the MiniMed™ 780G advanced hybrid closed-loop (AHCL) system maintains similar glycemic control across two different phases of the menstrual cycle in women with type 1 diabetes (T1D) and to analyze the system’s performance in these situations.
Methods:
Continuous glucose monitoring (CGM) and insulin delivery metrics from 12 participants with T1D using the MiniMed™ 780G AHCL were analyzed throughout 3 prospectively recorded, consecutive menstrual cycles (36 cycles in total). Mixed models were used to compare the different variables between the early follicular phase and late luteal phase.
Results:
A higher average glucose was found throughout the late luteal phase compared with the early follicular phase (139.5 [133.5, 145.2] vs. 131.5 [126.8, 140.2] mg/dl, respectively, P = 0.002), together with an increase in total daily insulin dose (37.2 ± 11.9 vs. 33.6 ± 12.2 IU, P < 0.001). However, similar values between phases were observed for most of the remaining CGM metrics, including time in range (83.0 [76.0, 87.5] vs. 85.0 [79.8, 89.0] %, P = 0.101).
Conclusion:
Our results suggest that differences in glycemic control may be found across the menstrual cycle in women with T1D using the MiniMed™ 780G AHCL. Although higher average glucose levels may be expected in the late luteal phase, the deterioration of glycemic control during this phase may be mild with the MiniMed™ 780G AHCL, given the similarities for most of the CGM metrics with respect to the early follicular phase.
Get full access to this article
View all access options for this article.